핵의학 시장 : 규모, 점유율, 성장률, 세계 산업 분석, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of nuclear medicine Market

The global nuclear medicine market is experiencing strong expansion driven by increasing adoption of radiopharmaceuticals for both diagnostic imaging and targeted therapy. In 2025, the market was valued at USD 11.77 billion. In 2026, it is projected to grow to USD 13.72 billion, reflecting rising clinical adoption and improved isotope availability. By 2034, the market is expected to reach USD 55.75 billion, growing at a CAGR of 19.15% during 2026-2034.

North America dominated the market in 2025 with a 52.67% share, supported by advanced imaging infrastructure, strong radiopharmaceutical manufacturing capacity, and high usage of PET and SPECT procedures.

Market Overview and Scope

Nuclear medicine involves the use of radiopharmaceuticals for diagnosing and treating diseases such as cancer, cardiovascular disorders, and neurological conditions. It includes PET and SPECT imaging for diagnostics and targeted radionuclide therapy for treatment.

The market is expanding due to rising prevalence of chronic diseases, increasing demand for early and precise diagnosis, and growing adoption of theranostics. Advancements in radioisotope production, imaging systems, and AI-supported diagnostics are further enhancing clinical efficiency and treatment outcomes.

Market Drivers

A key driver of the nuclear medicine market is the increasing use of radiopharmaceuticals in targeted therapy. These therapies allow radiation to directly target diseased cells while minimizing damage to healthy tissues, improving treatment precision and patient outcomes.

Growing approvals of radioligand therapies and expanding clinical applications in oncology are significantly boosting demand. Investments by companies in isotope production, manufacturing facilities, and global distribution networks are also improving product availability.

Market Restraints

High costs of radiopharmaceuticals and inadequate reimbursement policies remain major barriers to market growth. The production, handling, and delivery of nuclear medicine products require specialized infrastructure and strict safety protocols, increasing overall treatment costs.

Limited reimbursement coverage reduces hospital adoption and restricts patient access to advanced diagnostic and therapeutic procedures, particularly in emerging markets.

Market Opportunities

The integration of artificial intelligence into radiopharmaceutical development and imaging workflows is creating strong growth opportunities. AI helps improve target identification, optimize treatment planning, and enhance diagnostic accuracy.

Expansion of theranostics, which combines diagnosis and therapy, is also opening new clinical applications, especially in oncology. Emerging markets offer further opportunities due to rising healthcare investments and increasing disease burden.

Market Segmentation Analysis

By type, diagnostics dominated the market in 2025 due to widespread use of PET and SPECT imaging for disease detection, staging, and monitoring. Therapeutics is expected to grow at a CAGR of 25.74%, driven by increasing use of radioligand therapies and targeted alpha treatments.

By application, oncology accounted for the largest share in 2025 as nuclear medicine plays a critical role in cancer detection and treatment planning. Neurology is expected to grow at a CAGR of 18.70% due to increasing applications in brain disorder diagnosis.

By end user, hospitals and clinics dominated the market in 2025 due to high patient volumes and availability of advanced imaging infrastructure. Diagnostic centers are also expanding rapidly as outpatient imaging demand increases.

Regional Insights

North America led the global market in 2025 with USD 6.20 billion, maintaining its dominance due to strong clinical adoption and advanced radiopharmaceutical infrastructure. The U.S. market is projected at USD 6.81 billion in 2026.

Europe is expected to reach USD 2.21 billion in 2026, driven by strong research activity and expanding theranostic applications. Asia Pacific is projected at USD 2.23 billion in 2026, supported by healthcare infrastructure expansion in China, Japan, and India.

Latin America is expected to reach USD 0.69 billion in 2026, while the Middle East & Africa region, including GCC countries, is projected at USD 0.31 billion.

Competitive Landscape

The nuclear medicine market is semi-fragmented with key players including Novartis AG, Lantheus Holdings, Curium, Bracco, Siemens Healthineers, Bayer AG, and GE HealthCare. These companies are focusing on radiopharmaceutical expansion, acquisitions, and manufacturing capacity enhancement.

Strategic moves such as SHINE's acquisition of Lantheus' SPECT business and Novartis expanding radioligand manufacturing facilities highlight strong industry consolidation and growth momentum.

Conclusion

The global nuclear medicine market is projected to grow from USD 11.77 billion in 2025 to USD 13.72 billion in 2026 and reach USD 55.75 billion by 2034. Strong demand for precision diagnostics, increasing adoption of radiopharmaceutical therapies, and technological advancements in imaging and theranostics will continue to drive long-term market growth.

Segmentation By Type, Application, End User, and Region

By Type * Diagnostics

• PET Radiopharmaceuticals
• FDG-PET/18F
• 68Ga
• 68Cu
• 11C
• Others
  • SPECT Radiopharmaceuticals
• Technetium-99m
• Iodine-123
• Xenon-133
• Thallium-201
• Others
• Therapeutics
  • Ra-223
  • Sm-153
  • Lu-177
  • I-131
  • Y-90
  • Others

By Application * Neurology

• Cardiology
• Oncology
• Others

By End-user * Hospitals & Clinics

• Diagnostic Centers
• Others

By Region * North America (By Type, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Type, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Installed Base of PET/PET CT Scanners (Estimated), By Key Countries, 2025
• 4.2. Installed Base of Gamma Cameras (Estimated), By Key Countries, 2025
• 4.3. PET/PET CT Procedure Volume (Estimated), By Key Countries, 2025
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Overview: Ga-68 Demand
• 4.6. Overview: Radioisotope Generators, Current & Future Trends
• 4.7. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
• 4.8. Impact of COVID-19 on the Market
• 4.9. Regulatory Overview: Key Countries/ Region
• 4.10. Brief Profiles of Key Manufacturers, Cyclotrons
• 4.11. Supply Chain Analysis: Radioisotopes

5. Global Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Diagnostics
    • 5.1.1.1. PET Radiopharmaceuticals
      • 5.1.1.1.1. FDG-PET/18F
      • 5.1.1.1.2. 68Ga
      • 5.1.1.1.3. 68Cu
      • 5.1.1.1.4. 11C
      • 5.1.1.1.5. Others
    • 5.1.1.2. SPECT Radiopharmaceuticals
      • 5.1.1.2.1. Technetium-99m
      • 5.1.1.2.2. Iodine-123
      • 5.1.1.2.3. Xenon-133
      • 5.1.1.2.4. Thallium-201
      • 5.1.1.2.5. Others
  • 5.1.2. Therapeutics
    • 5.1.2.1. Ra-223
    • 5.1.2.2. Sm-153
    • 5.1.2.3. Lu-177
    • 5.1.2.4. I-131
    • 5.1.2.5. Y-90
    • 5.1.2.6. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Neurology
  • 5.2.2. Cardiology
  • 5.2.3. Oncology
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Diagnostic Centers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Diagnostics
    • 6.1.1.1. PET Radiopharmaceuticals
      • 6.1.1.1.1. FDG-PET/18F
      • 6.1.1.1.2. 68Ga
      • 6.1.1.1.3. 68Cu
      • 6.1.1.1.4. 11C
      • 6.1.1.1.5. Others
    • 6.1.1.2. SPECT Radiopharmaceuticals
      • 6.1.1.2.1. Technetium-99m
      • 6.1.1.2.2. Iodine-123
      • 6.1.1.2.3. Xenon-133
      • 6.1.1.2.4. Thallium-201
      • 6.1.1.2.5. Others
  • 6.1.2. Therapeutics
    • 6.1.2.1. Ra-223
    • 6.1.2.2. Sm-153
    • 6.1.2.3. Lu-177
    • 6.1.2.4. I-131
    • 6.1.2.5. Y-90
    • 6.1.2.6. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Neurology
  • 6.2.2. Cardiology
  • 6.2.3. Oncology
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Diagnostic Centers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Diagnostics
    • 7.1.1.1. PET Radiopharmaceuticals
      • 7.1.1.1.1. FDG-PET/18F
      • 7.1.1.1.2. 68Ga
      • 7.1.1.1.3. 68Cu
      • 7.1.1.1.4. 11C
      • 7.1.1.1.5. Others
    • 7.1.1.2. SPECT Radiopharmaceuticals
      • 7.1.1.2.1. Technetium-99m
      • 7.1.1.2.2. Iodine-123
      • 7.1.1.2.3. Xenon-133
      • 7.1.1.2.4. Thallium-201
      • 7.1.1.2.5. Others
  • 7.1.2. Therapeutics
    • 7.1.2.1. Ra-223
    • 7.1.2.2. Sm-153
    • 7.1.2.3. Lu-177
    • 7.1.2.4. I-131
    • 7.1.2.5. Y-90
    • 7.1.2.6. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Neurology
  • 7.2.2. Cardiology
  • 7.2.3. Oncology
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Diagnostic Centers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Diagnostics
    • 8.1.1.1. PET Radiopharmaceuticals
      • 8.1.1.1.1. FDG-PET/18F
      • 8.1.1.1.2. 68Ga
      • 8.1.1.1.3. 68Cu
      • 8.1.1.1.4. 11C
      • 8.1.1.1.5. Others
    • 8.1.1.2. SPECT Radiopharmaceuticals
      • 8.1.1.2.1. Technetium-99m
      • 8.1.1.2.2. Iodine-123
      • 8.1.1.2.3. Xenon-133
      • 8.1.1.2.4. Thallium-201
      • 8.1.1.2.5. Others
  • 8.1.2. Therapeutics
    • 8.1.2.1. Ra-223
    • 8.1.2.2. Sm-153
    • 8.1.2.3. Lu-177
    • 8.1.2.4. I-131
    • 8.1.2.5. Y-90
    • 8.1.2.6. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Neurology
  • 8.2.2. Cardiology
  • 8.2.3. Oncology
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Diagnostic Centers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Southeast Asia
  • 8.4.5. Australia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Diagnostics
    • 9.1.1.1. PET Radiopharmaceuticals
      • 9.1.1.1.1. FDG-PET/18F
      • 9.1.1.1.2. 68Ga
      • 9.1.1.1.3. 68Cu
      • 9.1.1.1.4. 11C
      • 9.1.1.1.5. Others
    • 9.1.1.2. SPECT Radiopharmaceuticals
      • 9.1.1.2.1. Technetium-99m
      • 9.1.1.2.2. Iodine-123
      • 9.1.1.2.3. Xenon-133
      • 9.1.1.2.4. Thallium-201
      • 9.1.1.2.5. Others
  • 9.1.2. Therapeutics
    • 9.1.2.1. Ra-223
    • 9.1.2.2. Sm-153
    • 9.1.2.3. Lu-177
    • 9.1.2.4. I-131
    • 9.1.2.5. Y-90
    • 9.1.2.6. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Neurology
  • 9.2.2. Cardiology
  • 9.2.3. Oncology
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Diagnostic Centers
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Diagnostics
    • 10.1.1.1. PET Radiopharmaceuticals
      • 10.1.1.1.1. FDG-PET/18F
      • 10.1.1.1.2. 68Ga
      • 10.1.1.1.3. 68Cu
      • 10.1.1.1.4. 11C
      • 10.1.1.1.5. Others
    • 10.1.1.2. SPECT Radiopharmaceuticals
      • 10.1.1.2.1. Technetium-99m
      • 10.1.1.2.2. Iodine-123
      • 10.1.1.2.3. Xenon-133
      • 10.1.1.2.4. Thallium-201
      • 10.1.1.2.5. Others
  • 10.1.2. Therapeutics
    • 10.1.2.1. Ra-223
    • 10.1.2.2. Sm-153
    • 10.1.2.3. Lu-177
    • 10.1.2.4. I-131
    • 10.1.2.5. Y-90
    • 10.1.2.6. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Neurology
  • 10.2.2. Cardiology
  • 10.2.3. Oncology
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals & Clinics
  • 10.3.2. Diagnostic Centers
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GE HealthCare
  • 11.2.2. Lantheus Holdings, Inc.
  • 11.2.3. Nordion (Canada) Inc. (Sotera Health)
  • 11.2.4. Bracco
  • 11.2.5. Curium
  • 11.2.6. Bayer AG
  • 11.2.7. Siemens Healthineers AG
  • 11.2.8. Novartis AG
  • 11.2.9. Jubilant Pharmova Limited
  • 11.2.10. Cardinal Health
  • 11.2.11. Norgine
  • 11.2.12. DuchemBio, Co., Ltd.